ArticleFrontiers in pediatrics2026
PROX1-associated lymphatic reprogramming signatures in pediatric adamantinomatous craniopharyngioma: a comparative study with adult cases.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adamantinomatous craniopharyngioma (ACP) is the most common sellar tumor in children. Although histologically benign, pediatric ACP often exhibits marked local invasiveness and a high postoperative recurrence rate. Emerging evidence suggests that the tumor microenvironment (TME), particularly immune infiltration and lymphatic-related structures, may play an important role in ACP progression. However, the presence and clinical relevance of lymphatic reprogramming in ACP remain poorly understood. Methods: Publicly available single-cell RNA sequencing data from a pediatric ACP specimen were analyzed to characterize cellular composition and PROX1 expression patterns. Immunohistochemistry was subsequently performed on pediatric and adult ACP tissues to examine the spatial distribution and age-related expression of lymphatic markers, including PROX1 and LYVE1, as well as the vascular endothelial marker CD34. Quantitative comparisons between pediatric and adult cohorts were conducted. Results: Single-cell analysis identified ten major cell populations within pediatric ACP, with epithelial cells accounting for approximately 40% of total PROX1 expression. Immunohistochemical validation revealed strong PROX1 expression predominantly localized to palisade-like and keratinized epithelial regions, while glial scar areas were largely negative. LYVE1-positive lymphatic-like structures were observed within the tumor parenchyma and showed partial spatial overlap with CD34-positive vascular structures, supporting the presence of PROX1-mediated lymphatic reprogramming. Notably, PROX1 and LYVE1 expression levels were significantly higher in pediatric ACP than in adult cases, indicating a marked age-dependent difference. Conclusions: Our findings demonstrate the presence of lymphatic-like structures characterized by PROX1 and LYVE1 expression in pediatric ACP, indicating that lymphatic-like reprogramming is associated with the tumor microenvironment. These features could potentially relate to the aggressive and infiltrative clinical behavior observed in pediatric cases. Therefore, exploring the modulation of PROX1-driven pathways warrants further investigation as a potential approach for pediatric ACP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.